Hankinson S E, Willett W C, Colditz G A, Hunter D J, Michaud D S, Deroo B, Rosner B, Speizer F E, Pollak M
Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Lancet. 1998 May 9;351(9113):1393-6. doi: 10.1016/S0140-6736(97)10384-1.
Insulin-like growth factor (IGF)-I, a mitogenic and antiapoptotic peptide, can affect the proliferation of breast epithelial cells, and is thought to have a role in breast cancer. We hypothesised that high circulating IGF-I concentrations would be associated with an increased risk of breast cancer.
We carried out a nested case-control study within the prospective Nurses' Health Study cohort. Plasma concentrations of IGF-I and IGF binding protein 3 (IGFBP-3) were measured in blood samples collected in 1989-90. We identified 397 women who had a diagnosis of breast cancer after this date and 620 age-matched controls. IGF-I concentrations were compared by logistic regression with adjustment for other breast-cancer risk factors.
There was no association between IGF-I concentrations and breast-cancer risk among the whole study group. In postmenopausal women there was no association between IGF-I concentrations and breast-cancer risk (top vs bottom quintile of IGF-I, relative risk 0.85 [95% CI 0.53-1.39]). The relative risk of breast cancer among premenopausal women by IGF-I concentration (top vs bottom tertile) was 2.33 (1.06-5.16; p for trend 0.08). Among premenopausal women less than 50 years old at the time of blood collection, the relative risk was 4.58 (1.75-12.0; p for trend 0.02). After further adjustment for plasma IGFBP-3 concentrations these relative risks were 2.88 and 7.28, respectively.
A positive relation between circulating IGF-I concentration and risk of breast cancer was found among premenopausal but not postmenopausal women. Plasma IGF-I concentrations may be useful in the identification of women at high risk of breast cancer and in the development of risk reduction strategies. Additional larger studies of this association among premenopausal women are needed to provide more precise estimates of effect.
胰岛素样生长因子(IGF)-I是一种有丝分裂原和抗凋亡肽,可影响乳腺上皮细胞的增殖,被认为在乳腺癌中起作用。我们假设循环中IGF-I浓度升高与乳腺癌风险增加有关。
我们在前瞻性护士健康研究队列中进行了一项巢式病例对照研究。1989 - 1990年采集的血样中测量了IGF-I和IGF结合蛋白3(IGFBP-3)的血浆浓度。我们确定了397名在此日期后被诊断为乳腺癌的女性和620名年龄匹配的对照。通过逻辑回归比较IGF-I浓度,并对其他乳腺癌风险因素进行调整。
在整个研究组中,IGF-I浓度与乳腺癌风险之间没有关联。在绝经后女性中,IGF-I浓度与乳腺癌风险之间没有关联(IGF-I最高五分位数与最低五分位数相比,相对风险为0.85 [95%可信区间0.53 - 1.39])。根据IGF-I浓度(最高三分位数与最低三分位数),绝经前女性患乳腺癌的相对风险为2.33(1.06 - 5.16;趋势p值为0.08)。在采血时年龄小于50岁的绝经前女性中,相对风险为4.58(1.75 - 12.0;趋势p值为0.02)。在进一步调整血浆IGFBP-3浓度后,这些相对风险分别为2.88和7.28。
在绝经前而非绝经后女性中发现循环IGF-I浓度与乳腺癌风险呈正相关。血浆IGF-I浓度可能有助于识别乳腺癌高危女性并制定降低风险策略。需要对绝经前女性中这种关联进行更多更大规模的研究,以提供更精确的效应估计。